A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors

Oral Oncol. 2020 Nov:110:104900. doi: 10.1016/j.oraloncology.2020.104900. Epub 2020 Jul 20.

Abstract

Background: ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments.

Patients and methods: This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.

Keywords: Head and neck cancer; Immunotherapy; Metastatic; PD-1 inhibitors; Predictors; Response.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Immune Checkpoint Proteins / genetics
  • Immune Checkpoint Proteins / metabolism
  • Male
  • Middle Aged
  • Molecular Targeted Therapy* / adverse effects
  • Molecular Targeted Therapy* / methods
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Squamous Cell Carcinoma of Head and Neck / diagnosis
  • Squamous Cell Carcinoma of Head and Neck / drug therapy*
  • Squamous Cell Carcinoma of Head and Neck / etiology
  • Squamous Cell Carcinoma of Head and Neck / mortality*
  • Survival Rate
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors
  • Immune Checkpoint Proteins